<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CJC Open</journal-id><journal-id journal-id-type="iso-abbrev">CJC Open</journal-id><journal-title-group><journal-title>CJC Open</journal-title></journal-title-group><issn pub-type="epub">2589-790X</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11681348</article-id><article-id pub-id-type="pii">S2589-790X(24)00378-0</article-id><article-id pub-id-type="doi">10.1016/j.cjco.2024.08.012</article-id><article-categories><subj-group subj-group-type="heading"><subject>Sex and Gender in Heart Disease</subject><subj-group><subject>Original Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Long-Term Impact of Gender Differences After Transcatheter Aortic Valve Implantation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Iwata</surname><given-names>Juri</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Hayashida</surname><given-names>Kentaro</given-names></name><degrees>MD, PhD</degrees><email>khayashidamd@gmail.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Arita</surname><given-names>Ryo</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Moriizumi</surname><given-names>Tomonari</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Kajino</surname><given-names>Akiyoshi</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Sakata</surname><given-names>Shingo</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Ryuzaki</surname><given-names>Toshinobu</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Shinada</surname><given-names>Keitaro</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Tsuruta</surname><given-names>Hikaru</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Kato</surname><given-names>Jungo</given-names></name><degrees>MD, PhD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Takahashi</surname><given-names>Tatsuo</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>Yamazaki</surname><given-names>Masataka</given-names></name><degrees>MD, PhD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au13"><name><surname>Shimizu</surname><given-names>Hideyuki</given-names></name><degrees>MD, PhD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au14"><name><surname>Ieda</surname><given-names>Masaki</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><aff id="aff1"><label>a</label>Department of Cardiology, Keio University School of Medicine, Tokyo, Japan</aff><aff id="aff2"><label>b</label>Department of Anesthesiology, Keio University School of Medicine, Tokyo, Japan</aff><aff id="aff3"><label>c</label>Department of Cardiovascular Surgery, Keio University School of Medicine, Tokyo, Japan</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author: Kentaro Hayashida, MD, PhD, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Tel.: +81-3-3353-1211; fax: +81-3-5363-3645 <email>khayashidamd@gmail.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>30</day><month>8</month><year>2024</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>30</day><month>8</month><year>2024</year></pub-date><volume>6</volume><issue>12</issue><fpage>1453</fpage><lpage>1461</lpage><history><date date-type="received"><day>9</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>8</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0015"><sec><title>Background</title><p>The short-term and midterm impact of gender differences on transcatheter aortic valve implantation (TAVI) has been studied. However, the impact on long-term clinical outcomes remains unclear. The objective of the study was to investigate the impact of gender differences after TAVI on long-term clinical outcomes and structural valve deterioration (SVD).</p></sec><sec><title>Methods</title><p>Of the 672 consecutive patients who underwent TAVI, with balloon- or self-expandable valves, between 2013 and 2018, a total of 511 who underwent multidetector computed tomography analysis within 30 days after TAVI were included. Echocardiographic data were analyzed annually.</p></sec><sec><title>Results</title><p>The number of women was 343 (67.2%), and 90.7% of them had a small annulus (&#x0003c; 430 mm<sup>2</sup>). The effective orifice area was significantly smaller in women compared with that in men, whereas no difference occurred in the incidence of prosthesis&#x02013;patient mismatch. The incidence of leaflet thrombosis detected by multidetector computed tomography was similar for women vs men (15.2% vs 13.1%, respectively; <italic>P</italic>&#x000a0;= 0.53). During the median follow-up of 1844 days (interquartile range: 1190-2311 days), women showed a significantly decreased incidence of all-cause mortality (hazard ratio, 0.69; 95% confidence interval, 0.54-0.90; <italic>P</italic>&#x000a0;= 0.005). The development of SVD was comparable (hazard ratio, 0.99; 95% confidence interval, 0.78-1.25, <italic>P</italic>&#x000a0;= 0.90). Severe frailty and the balloon-expandable valves were the independent risk factors for all-cause mortality and SVD in women, respectively.</p></sec><sec><title>Conclusions</title><p>Women had superior long-term clinical outcomes, compared with those of men, despite their having a small annulus. During long-term follow-up, the incidence of SVD in women was similar in the entire cohort, compared to that in men; however, balloon-expandable valves were possible risk factors for SVD in women.</p></sec></abstract><abstract abstract-type="graphical" id="abs0020"><title>Graphical abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="ga1"/></fig></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Contexte</title><p>Les effets &#x000e0; court et &#x000e0; moyen terme de l'implantation valvulaire aortique par cath&#x000e9;ter (IVAC) chez les hommes et chez les femmes ont &#x000e9;t&#x000e9; &#x000e9;tudi&#x000e9;s. Cependant, les r&#x000e9;sultats cliniques &#x000e0; long terme en fonction du sexe demeurent n&#x000e9;buleux. L&#x02019;&#x000e9;tude avait pour objectif d&#x02019;&#x000e9;valuer dans quelle mesure le sexe a une influence sur les r&#x000e9;sultats cliniques &#x000e0; long terme et sur la d&#x000e9;t&#x000e9;rioration structurelle de la valve (DSV) apr&#x000e8;s une IVAC.</p></sec><sec><title>M&#x000e9;thodologie</title><p>Parmi les 672 patients cons&#x000e9;cutifs qui ont subi une IVAC, par une proth&#x000e8;se valvulaire sur ballonnet ou auto-extensible entre 2013 et 2018, un total de 511 patients qui avaient pass&#x000e9; une analyse par tomodensitom&#x000e9;trie multid&#x000e9;tecteurs au cours des 30 jours suivant l'IVAC ont &#x000e9;t&#x000e9; retenus. Les donn&#x000e9;es d&#x02019;&#x000e9;chocardiographie ont &#x000e9;t&#x000e9; analys&#x000e9;es sur une base annuelle.</p></sec><sec><title>R&#x000e9;sultats</title><p>Il y avait 343 (67,2 %) femmes; chez 90,7 % d&#x02019;entre elles, l&#x02019;anneau &#x000e9;tait petit (&#x0003c; 430 mm<sup>2</sup>). La surface valvulaire effective &#x000e9;tait consid&#x000e9;rablement plus petite chez les femmes que chez les hommes, m&#x000ea;me si aucune diff&#x000e9;rence n&#x02019;a &#x000e9;t&#x000e9; observ&#x000e9;e quant &#x000e0; la fr&#x000e9;quence des incompatibilit&#x000e9;s proth&#x000e8;se-patient. La fr&#x000e9;quence de thrombose valvulaire d&#x000e9;tect&#x000e9;e par tomodensitom&#x000e9;trie multid&#x000e9;tecteurs &#x000e9;tait similaire chez les femmes et chez les hommes (respectivement 15,2 % vs 13,1&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0,53). Durant le suivi m&#x000e9;dian de 1&#x000a0;844 jours (&#x000e9;cart interquartile :&#x000a0;1&#x000a0;190-2&#x000a0;311 jours), le taux de mortalit&#x000e9; toutes causes confondues a consid&#x000e9;rablement diminu&#x000e9; chez les femmes (rapport de risques instantan&#x000e9;s [RRI], 0,69; intervalle de confiance [IC] &#x000e0; 95 % : 0,54-0,90; <italic>p</italic>&#x000a0;= 0,005). L&#x02019;apparition d&#x02019;une DSV &#x000e9;tait comparable (RRI, 0,99; IC &#x000e0; 95&#x000a0;% : 0,78-1,25, <italic>p</italic>&#x000a0;= 0,90). Une fragilit&#x000e9; s&#x000e9;v&#x000e8;re et des valves sur ballonnet&#x000a0;constituaient les facteurs de risques ind&#x000e9;pendants de mortalit&#x000e9;&#x000a0;toutes causes confondues et de DSV chez les femmes, respectivement.</p></sec><sec><title>Conclusions</title><p>M&#x000ea;me avec un anneau plus petit, les r&#x000e9;sultats &#x000e0; long terme &#x000e9;taient sup&#x000e9;rieurs chez les femmes comparativement aux hommes. Pendant le suivi &#x000e0; long terme, la fr&#x000e9;quence de la DSV observ&#x000e9;e chez les femmes &#x000e9;tait similaire pour l&#x02019;ensemble de la cohorte, comparativement &#x000e0; celle observ&#x000e9;e chez les hommes; toutefois, les valves sur ballonnet repr&#x000e9;sentaient un facteur de risque possible de DSV chez les femmes.</p></sec></trans-abstract></article-meta></front><body><p id="p0010">The indications for transcatheter aortic valve implantation (TAVI) have been extended to younger, lower-risk patients.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref> Generally, women have a better prognosis after TAVI if the outcomes are limited to those in midterm data.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> However, the long-term prognostic differences based on gender remain unclear. Furthermore, women have a smaller aortic anatomy than men do, owing to their smaller body size; however, the effect of their smaller annulus on valve durability has not been clarified. Therefore, in the era of expanding indications for TAVI, elucidation of gender differences in clinical outcomes and valve durability during long-term follow-up is imperative. Thus, in this study, we aimed to investigate the impact of gender differences on prognosis and structural valve deterioration (SVD) after TAVI, based on long-term follow-up data.</p><sec id="sec1"><title>Methods</title><sec id="sec1.1"><title>Study cohort and data collection</title><p id="p0015">This study was conducted at the Keio University Hospital. The authors confirm that patient consent forms have been obtained for this article. The Keio University School of Medicine Ethics Committee approved the study protocol (institutional review board information reference numbers: 20130270, UMIN000020423), and this study complied with the principles of the Declaration of Helsinki.</p><p id="p0020">This study included consecutive patients who underwent transfemoral or transapical TAVI using balloon-expandable valves (SAPIEN XT or SAPIEN 3; Edwards Lifesciences, Irvine, CA) or self-expandable valves (CoreValve, Evolut R, or Evolut PRO, Medtronic, Minneapolis, MN) between October 2013 and December 2018 at our centre. We excluded patients who did not undergo multidetector computed tomography (MDCT) within 30 days after TAVI, due to their having either severe chronic kidney disease, allergy to contrast, or asthma, and those who participated in other clinical trials. An institutional Heart Team determined the device selection.</p><p id="p0025">The baseline clinical, procedural, and follow-up data were prospectively captured and recorded in a dedicated database. All procedural complications were defined following the Valve Academic Research Consortium (VARC)-3 criteria and were collected systematically.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Regular follow-ups were scheduled to occur at 1 month, and annually after that. Clinical follow-up data were collected during outpatient visits to our centre, and via documentation from referring physicians, and telephone interviews.</p></sec><sec id="sec1.2"><title>MDCT analysis</title><p id="p0030">MDCT was performed preoperatively and within 30 days of TAVI. Based on the updated VARC-3 criteria, hypoattenuated leaflet thickening (HALT) was defined as the hypoattenuating thickening of one or more leaflets identified visually using MDCT. The extent of HALT was measured per leaflet, using a 4-tier grading scale for leaflet involvement along a curvilinear contour, assuming maximum involvement from the base of the leaflet.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> The presence of HALT was evaluated if at least one grade-1 or greater leaflet was present. Two experienced cardiologists (J.I. and K.H.) evaluated all transcatheter heart valves twice, using contrast-enhanced electrocardiogram-gated MDCT data. All MDCT analyses were performed using 3mensio Structural Heart 10.2 (Pie Medical Imaging, Maastricht, Netherlands).</p></sec><sec id="sec1.3"><title>Echocardiography and laboratory tests</title><p id="p0035">Transthoracic echocardiography and laboratory tests were performed before the procedure, at discharge, and during the annual follow-up after TAVI. Prosthesis&#x02013;patient mismatch (PPM) was categorized&#x02014;based on prosthesis effective orifice area (EOA) indexed to body surface area&#x02014;as severe (&#x02264; 0.65 cm<sup>2</sup>/m<sup>2</sup>) or moderate (&#x0003e; 0.65-0.85 cm<sup>2</sup>/m<sup>2</sup>) in the nonobese population, and as severe (&#x02264; 0.55 cm<sup>2</sup>/m<sup>2</sup>) or moderate (&#x0003e; 0.55-0.70 cm<sup>2</sup>/m<sup>2</sup>) in the obese population (body mass index &#x02265; 30 kg/m<sup>2</sup>).<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> SVD was defined according to the VARC-3 criteria and was categorized as severe (category 1: increase in mean pressure gradient (MPG) &#x02265; 20 mm Hg, resulting in an MPG &#x02265; 30 mm Hg, with a concomitant decrease in EOA &#x02265; 0.6 cm<sup>2</sup> or &#x02265; 50%, and/or a decrease in Doppler velocity index of &#x02265; 0.2 or &#x02265; 40%; category 2: new occurrence of or increase of &#x02265; 2 grades of valvular regurgitation, resulting in severe aortic regurgitation) or moderate (category 1: increase in MPG &#x02265; 10 mm Hg, resulting in an MPG &#x02265; 20 mm Hg, with a concomitant decrease in EOA &#x02265; 0.3 cm<sup>2</sup> or &#x02265; 25%, and a decrease in the Doppler velocity index of &#x02265; 0.1 or &#x02265; 20%; category 2: a new occurrence of or increase of &#x02265; 1 grade of valvular regurgitation, resulting in increased moderate aortic regurgitation).<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> In this study, patients with SVD who met the VARC-3 definition of moderate or greater severity were defined as having SVD. The mode of failure was either stenosis or regurgitation. Experienced echocardiographers analyzed the results.</p><p id="p0040">Chronic kidney disease was defined as the presence of an estimated glomerular filtration rate of &#x0003c; 60 mL/min per 1.73 m<sup>2</sup>.</p></sec><sec id="sec1.4"><title>Endpoint definitions</title><p id="p0045">The main endpoint of this study was all-cause mortality during long-term follow-up after TAVI. Other clinical endpoints, including cardiovascular death, stroke, rehospitalization for heart failure, and SVD development, also were evaluated.</p></sec><sec id="sec1.5"><title>Statistical analysis</title><p id="p0050">Categorical variables were reported as frequencies and percentages, and differences were evaluated using the &#x003c7;<sup>2</sup> test or a 2-tailed Fisher exact test. Continuous variables are presented as mean &#x000b1; standard deviation, or as median with interquartile range, comparisons between groups were made using the 2-sample <italic>t</italic> test or the Mann&#x02013;Whitney <italic>U</italic> test, as appropriate. Time-to-event curves were generated using the Kaplan&#x02013;Meier method (censored at death or last valid contact, awaiting the subsequent follow-up, or consent withdrawal). The Cox proportional hazards model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of the clinical endpoints. A multivariate logistic regression model was constructed based on the 8 baseline variables that may have affected the study outcomes. The variables included clinical age, HALT levels, body mass index, valve type (balloon-expandable or self-expandable), left ventricular ejection fraction, paravalvular leakage, PPM, clinical frailty scale score, chronic kidney disease, and chronic obstructive pulmonary disease.</p><p id="p0055">Statistical significance was set at a 2-sided <italic>P</italic>-value of &#x0003c; 0.05. All the data analyses were performed using SPSS statistical software, version 29.0 (IBM, Armonk, NY).</p></sec></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Study population and baseline characteristics</title><p id="p0060">Among the 672 consecutive patients who underwent TAVI between October 2013 and December 2018 at Keio University Hospital, 511 met the inclusion criteria and were analyzed (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>). A total of 343 of the 511 patients (67.2%) were women. The baseline characteristics of the study cohort are presented in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>. Baseline characteristics differed significantly between women and men. Women were older at the time of TAVI (mean age: 84.8 &#x000b1; 5.3 vs 83.8 &#x000b1; 5.3 years, <italic>P</italic>&#x000a0;= 0.025). They had a smaller body size (body mass index: 21.9 &#x000b1; 3.7 vs 22.8 &#x000b1; 3.2 kg/m<sup>2</sup>, <italic>P</italic>&#x000a0;= 0.002), a greater degree of frailty (clinical frailty scale score &#x02265; 4: 53.9% vs 32.1%, <italic>P</italic> &#x0003c; 0.001), more-significant shortness of breath (New York Heart Association class &#x02265; 3: 42.6% vs 31.5%, <italic>P</italic>&#x000a0;= 0.016), higher brain natriuretic peptide levels (230 [114-493] vs 165 [70-363] pg/mL, <italic>P</italic>&#x000a0;= 0.001), lower hemoglobin levels (11.1 &#x000b1; 1.4 vs 12.1 &#x000b1; 1.7 g/dL, <italic>P</italic> &#x0003c; 0.001), and a higher Society of Thoracic Surgeons score (6.5% &#x000b1; 3.4% vs 5.8% &#x000b1; 3.6%, <italic>P</italic>&#x000a0;= 0.002) than did men. Women were less likely to suffer from coronary artery disease (30.0% vs 45.8%, <italic>P</italic> &#x0003c; 0.001), chronic obstructive pulmonary disease (11.4% vs 26.2%, <italic>P</italic> &#x0003c; 0.001), and carotid artery stenosis (3.8% vs 8.9%, <italic>P</italic>&#x000a0;= 0.016) than were men, resulting in less previous history of percutaneous coronary intervention (18.7% vs 31.0%, <italic>P</italic>&#x000a0;= 0.002) or stroke (5.0% vs 9.5%, <italic>P</italic>&#x000a0;= 0.048).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Study cohort. MDCT, multidetector computed tomography; TAVI, transcatheter aortic valve implantation.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Women (n&#x000a0;= 343)</th><th>Men (n&#x000a0;= 168)</th><th><italic>P</italic></th></tr></thead><tbody><tr><td><bold>Preoperative</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;Age, y</td><td>84.8 &#x000b1; 5.3</td><td>83.8 &#x000b1; 5.3</td><td align="char">0.025</td></tr><tr><td>&#x000a0;STS score, %</td><td>6.5 &#x000b1; 3.4</td><td>5.8 &#x000b1; 3.6</td><td align="char">0.002</td></tr><tr><td>&#x000a0;Body mass index, kg/m<sup>2</sup></td><td>21.9 &#x000b1; 3.7</td><td>22.8 &#x000b1; 3.2</td><td align="char">0.002</td></tr><tr><td>&#x000a0;Clinical frailty scale score &#x02265; 4</td><td align="char">185 (53.9)</td><td align="char">54 (32.1)</td><td align="char">&#x0003c; 0.001</td></tr><tr><td>&#x000a0;NYHA class 3 or 4</td><td align="char">146 (42.6)</td><td align="char">53 (31.5)</td><td align="char">0.016</td></tr><tr><td>&#x000a0;Albumin, g/dL</td><td>3.8 &#x000b1; 0.4</td><td>3.9 &#x000b1; 0.4</td><td align="char">0.088</td></tr><tr><td>&#x000a0;Hemoglobin, g/dL</td><td>11.1 &#x000b1; 1.4</td><td>12.1 &#x000b1; 1.7</td><td align="char">&#x0003c; 0.001</td></tr><tr><td>&#x000a0;BNP, pg/mL (median and interquartile range)</td><td align="char">230 (114&#x02013;493)</td><td align="char">165 (70&#x02013;363)</td><td align="char">0.001</td></tr><tr><td><bold>Concomitant disease</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;Hypertension</td><td align="char">270 (78.7)</td><td align="char">137 (81.5)</td><td align="char">0.46</td></tr><tr><td>&#x000a0;Dyslipidemia</td><td align="char">185 (53.9)</td><td align="char">93 (55.4)</td><td align="char">0.76</td></tr><tr><td>&#x000a0;Coronary artery disease</td><td align="char">103 (30.0)</td><td align="char">77 (45.8)</td><td align="char">&#x0003c; 0.001</td></tr><tr><td>&#x000a0;Diabetes mellitus</td><td align="char">82 (23.9)</td><td align="char">52 (31.0)</td><td align="char">0.089</td></tr><tr><td>&#x000a0;History of atrial fibrillation</td><td align="char">70 (20.4)</td><td align="char">34 (20.2)</td><td align="char">0.96</td></tr><tr><td>&#x000a0;Chronic kidney disease (GFR&#x0003c; 60 mL/min/1.73 m&#x000b2;)</td><td align="char">251 (73.2)</td><td align="char">118 (70.2)</td><td align="char">0.49</td></tr><tr><td>&#x000a0;Peripheral artery disease</td><td align="char">35 (10.2)</td><td align="char">22 (13.1)</td><td align="char">0.33</td></tr><tr><td>&#x000a0;COPD</td><td align="char">39 (11.4)</td><td align="char">44 (26.2)</td><td align="char">&#x0003c; 0.001</td></tr><tr><td>&#x000a0;Carotid artery stenosis</td><td align="char">13 (3.8)</td><td align="char">15 (8.9)</td><td align="char">0.016</td></tr><tr><td><bold>Previous history</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;Coronary artery bypass grafting</td><td align="char">14 (4.1)</td><td align="char">12 (7.1)</td><td align="char">0.14</td></tr><tr><td>&#x000a0;Percutaneous coronary intervention</td><td align="char">64 (18.7)</td><td align="char">52 (31.0)</td><td align="char">0.002</td></tr><tr><td>&#x000a0;Myocardial infarction</td><td align="char">11 (3.2)</td><td align="char">9 (5.4)</td><td align="char">0.24</td></tr><tr><td>&#x000a0;Stroke</td><td align="char">17 (5.0)</td><td align="char">16 (9.5)</td><td align="char">0.048</td></tr><tr><td>&#x000a0;Pacemaker</td><td align="char">16 (4.7)</td><td align="char">9 (5.4)</td><td align="char">0.73</td></tr><tr><td><bold>Echocardiographic variables</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;Peak flow velocity, m/s</td><td>4.65 &#x000b1; 0.75</td><td>4.50 &#x000b1; 0.66</td><td align="char">0.011</td></tr><tr><td>&#x000a0;Mean pressure gradient, mm Hg</td><td>50.9 &#x000b1; 18.0</td><td>47.5 &#x000b1; 15.4</td><td align="char">0.024</td></tr><tr><td>&#x000a0;Aortic valve area, cm<sup>2</sup></td><td>0.59 &#x000b1; 0.16</td><td>0.71 &#x000b1; 0.19</td><td align="char">&#x0003c; 0.001</td></tr><tr><td>&#x000a0;Index aortic valve area, cm<sup>2</sup>/m<sup>2</sup></td><td>0.44 &#x000b1; 0.11</td><td>0.44 &#x000b1; 0.12</td><td align="char">0.58</td></tr><tr><td>&#x000a0;Ejection fraction, % (Simpson)</td><td>62.6 &#x000b1; 11.3</td><td>62.5 &#x000b1; 11.7</td><td align="char">0.92</td></tr><tr><td>&#x000a0;Moderate or severe AR</td><td align="char">26 (7.6)</td><td align="char">9 (5.4)</td><td align="char">0.35</td></tr><tr><td>&#x000a0;Moderate or severe MR</td><td align="char">35 (10.2)</td><td align="char">6 (3.6)</td><td align="char">0.01</td></tr><tr><td><bold>MDCT variables</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;Aortic annulus area, mm<sup>2</sup></td><td>365 &#x000b1; 52</td><td>445 &#x000b1; 61</td><td align="char">&#x0003c; 0.001</td></tr><tr><td>&#x000a0;Area &#x0003c; 430 mm<sup>2</sup></td><td align="char">311 (90.7)</td><td align="char">74 (44.0)</td><td align="char">&#x0003c; 0.001</td></tr><tr><td>&#x000a0;Right MLD, mm</td><td>6.1 &#x000b1; 0.9</td><td>6.7 &#x000b1; 1.2</td><td align="char">&#x0003c; 0.001</td></tr><tr><td>&#x000a0;Left MLD, mm</td><td>5.9 &#x000b1; 1.0</td><td>6.6 &#x000b1; 1.2</td><td align="char">&#x0003c; 0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Values are mean (&#x000b1; standard deviation), or count (%), unless otherwise indicated. <italic>P</italic>-values are from &#x003c7;<sup>2</sup> test (n x 2 comparisons) or Student <italic>t</italic>test (continuous parameters). AR, aortic regurgitation; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; MDCT, multidetector computed tomography; MLD, minimal lumen diameter; MR, mitral regurgitation; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons.</p></fn></table-wrap-foot></table-wrap></p><p id="p0065">Transthoracic echocardiography demonstrated a higher severity of aortic stenosis (peak flow velocity, 4.65 &#x000b1; 0.75 vs 4.50 &#x000b1; 0.66 m/s, <italic>P</italic>&#x000a0;= 0.011; aortic valve area, 0.59 &#x000b1; 0.16 vs 0.71 &#x000b1; 0.19 cm<sup>2</sup>, <italic>P</italic> &#x02264; 0.001; MPG, 50.9 &#x000b1; 18.0 vs 47.5 &#x000b1; 15.4 mm Hg, <italic>P</italic>&#x000a0;= 0.024) and a higher incidence of moderate or severe mitral valve regurgitation, 10.2% vs 3.6%, <italic>P</italic>&#x000a0;=&#x000a0;0.01) in women than in men.</p><p id="p0070">MDCT analysis demonstrated that the aortic annulus area was smaller in women than in men (365 &#x000b1; 52 vs 445 &#x000b1; 61 mm<sup>2</sup>, <italic>P</italic> &#x0003c; 0.001), and 90.7% of women had a smaller annulus, of &#x0003c; 430 mm<sup>2</sup>.</p></sec><sec id="sec2.2"><title>Procedural characteristics, complications, and echocardiographic outcomes within 30 days</title><p id="p0075">The procedures and complications are summarized in <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>. The implanted valve types were not significantly different for women vs men, although the valve size was smaller in women than in men, based on their annulus size. Notably, 20-mm balloon-expandable valves were used in women only.<table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Procedure outcomes and complications</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Procedure characteristics</th><th>Women (n&#x000a0;= 343)</th><th>Men (n&#x000a0;= 168)</th><th><italic>P</italic></th></tr></thead><tbody><tr><td><bold>Type of valve</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;<bold>Balloon-expandable valve</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;SAPIEN XT</td><td align="char">133 (38.8)</td><td align="char">65 (38.7)</td><td/></tr><tr><td>&#x000a0;SAPIEN 3</td><td align="char">165 (48.1)</td><td align="char">85 (50.6)</td><td/></tr><tr><td>&#x000a0;<bold>Self-expandable valve</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;CoreValve</td><td align="char">8 (2.3)</td><td align="char">3 (1.8)</td><td/></tr><tr><td>&#x000a0;Evolut R</td><td align="char">31 (9.0)</td><td align="char">13 (7.7)</td><td/></tr><tr><td>&#x000a0;Evolut PRO</td><td align="char">6 (1.7)</td><td align="char">2 (1.2)</td><td align="char">0.95</td></tr><tr><td><bold>Predilation</bold></td><td align="char">124 (36.2)</td><td align="char">63 (37.5)</td><td align="char">0.77</td></tr><tr><td><bold>Postdilation</bold></td><td align="char">84 (24.5)</td><td align="char">45 (26.8)</td><td align="char">0.58</td></tr><tr><td><bold>Valve size, mm</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;0</td><td align="char">37 (10.8)</td><td align="char">0 (0)</td><td/></tr><tr><td>&#x000a0;23</td><td align="char">231 (67.3)</td><td align="char">44 (26.2)</td><td/></tr><tr><td>&#x000a0;26</td><td align="char">65 (19.0)</td><td align="char">103 (61.3)</td><td/></tr><tr><td>&#x000a0;29</td><td align="char">10 (2.9)</td><td align="char">21 (12.5)</td><td align="char">&#x0003c; 0.001</td></tr><tr><td><bold>HALT within 30 d</bold></td><td align="char">52 (15.2)</td><td align="char">22 (13.1)</td><td align="char">0.53</td></tr><tr><td><bold>Procedural complications</bold></td><td/><td/><td/></tr><tr><td>&#x000a0;<bold>Stroke</bold></td><td align="char">6 (1.7)</td><td align="char">2 (1.2)</td><td align="char">0.63</td></tr><tr><td>&#x000a0;Ischemic</td><td align="char">6 (1.7)</td><td align="char">1 (0.6)</td><td align="char">0.29</td></tr><tr><td>&#x000a0;Hemorrhagic</td><td align="char">0 (0)</td><td align="char">1 (0.6)</td><td align="char">0.15</td></tr><tr><td>&#x000a0;Disabling</td><td align="char">3 (0.9)</td><td align="char">1 (0.6)</td><td align="char">0.74</td></tr><tr><td>&#x000a0;Transient ischemic attack</td><td align="char">0 (0)</td><td align="char">1 (0.6)</td><td align="char">0.15</td></tr><tr><td>&#x000a0;<bold>Bleeding</bold></td><td align="char">21 (6.1)</td><td align="char">7 (4.2)</td><td align="char">0.36</td></tr><tr><td>&#x000a0;Minor</td><td align="char">10 (2.9)</td><td align="char">2 (1.2)</td><td align="char">0.23</td></tr><tr><td>&#x000a0;Major and/or life-threatening</td><td align="char">12 (3.5)</td><td align="char">5 (3.0)</td><td align="char">0.76</td></tr><tr><td>&#x000a0;<bold>All vascular complications</bold></td><td align="char">49 (14.3)</td><td align="char">10 (6.0)</td><td align="char">0.006</td></tr><tr><td>&#x000a0;<bold>New permanent pacemaker</bold></td><td align="char">19 (5.5)</td><td align="char">15 (8.9)</td><td align="char">0.15</td></tr><tr><td><bold>Hospital stay, d</bold><bold>(median and interquartile range)</bold></td><td align="char">9 (7&#x02013;13)</td><td align="char">9 (7&#x02013;12)</td><td align="char">0.08</td></tr><tr><td><bold>Oral anticoagulant therapy</bold></td><td align="char">82 (23.9)</td><td align="char">36 (21.4)</td><td align="char">0.53</td></tr><tr><td><bold>No antithrombotic therapy</bold></td><td align="char">13 (3.8)</td><td align="char">4 (2.4)</td><td align="char">0.40</td></tr></tbody></table><table-wrap-foot><fn id="tspara0025"><p>Values are mean (&#x000b1; standard deviation), or count (%), unless otherwise indicated. <italic>P</italic>-values are from the Fisher test (2 x 2 comparison), the &#x003c7;<sup>2</sup> test (n x 2 comparisons), or the Student <italic>t</italic> test (continuous parameters). CoreValve, Evolut R, and Evolut PRO are from Medtronic (Minneapolis, MN); SAPIEN XT and SAPIEN 3 are from Edwards Lifesciences (Irvine, CA).</p></fn><fn id="tspara0030"><p>HALT, hypoattenuated leaflet thickening.</p></fn></table-wrap-foot></table-wrap></p><p id="p0080">MDCT analysis within 30 days after TAVI demonstrated that HALT was detected in 74 patients (14.5%) in total. Women and men showed no significant difference in the incidence of HALT (15.2% vs 13.1%, <italic>P</italic>&#x000a0;= 0.53).</p><p id="p0085">The incidence of vascular complications was significantly higher in women than in men (14.3% vs 6.0%, <italic>P</italic>&#x000a0;= 0.006). No significant differences were observed in the incidence of other procedural complications, including ischemic and/or hemorrhagic and/or disabling and/or transient ischemic stroke, major or life-threatening bleeding, or new permanent pacemaker implantation.</p><p id="p0090">The postprocedural echocardiographic data are shown in <xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>. The peak flow velocity, EOA, and MPG were less favourable in women than they were in men, for each type of balloon- and self-expandable valve. Hemodynamics were well improved in both genders after TAVI (for balloon-expandable valves&#x02014;peak flow velocity, 2.45 &#x000b1; 0.46 vs 2.26 &#x000b1; 0.41 m/s, <italic>P</italic> &#x0003c; 0.001; EOA, 1.45 &#x000b1; 0.35 vs 1.77 &#x000b1; 0.45 cm<sup>2</sup>, <italic>P</italic> &#x0003c; 0.001; MPG, 12.6 &#x000b1; 5.5 vs 10.3 &#x000b1; 4.0 mm Hg, <italic>P</italic> &#x0003c; 0.001; for self-expandable valves&#x02014;2.24 &#x000b1; 0.49 vs 1.91 &#x000b1; 0.37 m/s, <italic>P</italic>&#x000a0;= 0.011; 1.55 &#x000b1; 0.34 vs 1.91 &#x000b1; 0.49 cm<sup>2</sup>, <italic>P</italic>&#x000a0;= 0.004; 9.9 &#x000b1; 4.6 vs 7.3 &#x000b1; 3.1 mm Hg, <italic>P</italic>&#x000a0;= 0.009). However, no significant difference occurred in the indexed EOA. Furthermore, women and men showed no significant difference in incidence of PPM.<table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>Echocardiographic outcomes at discharge</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Measure</th><th colspan="3">Balloon-expandable valve<hr/></th><th colspan="3">Self-expandable valve<hr/></th></tr><tr><th>Women (n&#x000a0;= 298)</th><th>Men (n&#x000a0;= 150)</th><th><italic>P</italic></th><th>Women (n&#x000a0;= 45)</th><th>Men (n&#x000a0;= 18)</th><th><italic>P</italic></th></tr></thead><tbody><tr><td><bold>Discharge or postprocedure</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Peak flow velocity, m/s</td><td>2.45 &#x000b1; 0.46</td><td>2.26 &#x000b1; 0.41</td><td align="char">&#x0003c; 0.001</td><td>2.24 &#x000b1; 0.49</td><td>1.91 &#x000b1; 0.37</td><td align="char">0.011</td></tr><tr><td>&#x000a0;Effective orifice area, cm<sup>2</sup></td><td>1.45 &#x000b1; 0.35</td><td>1.77 &#x000b1; 0.45</td><td align="char">&#x0003c; 0.001</td><td>1.55 &#x000b1; 0.34</td><td>1.91 &#x000b1; 0.49</td><td align="char">0.004</td></tr><tr><td>&#x000a0;Index effective orifice area, cm<sup>2</sup>/m<sup>2</sup></td><td>1.08 &#x000b1; 0.27</td><td>1.11 &#x000b1; 0.31</td><td align="char">0.42</td><td>1.20 &#x000b1; 0.32</td><td>1.19 &#x000b1; 0.28</td><td align="char">0.99</td></tr><tr><td>&#x000a0;Prosthetic valve mean gradient, mm Hg</td><td>12.6 &#x000b1; 5.5</td><td>10.3 &#x000b1; 4.0</td><td align="char">&#x0003c; 0.001</td><td>9.9 &#x000b1; 4.6</td><td>7.3 &#x000b1; 3.1</td><td align="char">0.009</td></tr><tr><td>&#x000a0;Paravalvular regurgitation</td><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;None or trace</td><td align="char">144 (48.3)</td><td align="char">61 (40.7)</td><td/><td align="char">9 (20.0)</td><td align="char">3 (16.7)</td><td/></tr><tr><td>&#x000a0;Mild</td><td align="char">154 (51.7)</td><td align="char">88 (58.7)</td><td/><td align="char">34 (75.6)</td><td align="char">13 (72.2)</td><td/></tr><tr><td>&#x000a0;Moderate</td><td align="char">0 (0)</td><td align="char">1 (0.7)</td><td align="char">0.13</td><td align="char">2 (4.4)</td><td align="char">2 (11.1)</td><td align="char">0.61</td></tr><tr><td>&#x000a0;Prosthesis&#x02013;patient mismatch</td><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Insignificant</td><td align="char">242 (81.8)</td><td align="char">121 (80.7)</td><td/><td align="char">42 (93.3)</td><td align="char">17 (94.4)</td><td/></tr><tr><td>&#x000a0;Moderate</td><td align="char">46 (15.5)</td><td align="char">24 (16.0)</td><td/><td align="char">1 (2.2)</td><td align="char">1 (5.6)</td><td/></tr><tr><td>&#x000a0;Severe</td><td align="char">8 (2.7)</td><td align="char">5 (3.3)</td><td align="char">0.92</td><td align="char">2 (4.4)</td><td align="char">0 (0)</td><td align="char">0.54</td></tr></tbody></table><table-wrap-foot><fn><p>Values are mean (&#x000b1; standard deviation), or n (%). <italic>P</italic>-values are from the Fisher test for the SAPIEN XT (Edwards Lifesciences, Irvine, CA), the &#x003c7;<sup>2</sup> test for the SAPIEN 3 (Edwards Lifesciences), or the Student <italic>t</italic> test (continuous parameters).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.3"><title>Long-term clinical outcomes</title><p id="p0095">The median follow-up duration was 1844 days (interquartile range, 1190-2311 days), and the long-term clinical outcomes are presented in <xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref>. The Kaplan&#x02013;Meier curves depicting the incidences of all-cause mortality, cardiovascular death, and SVD, according to gender, are shown in <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>. Throughout the study period, the incidence of all-cause mortality was lower in women than in men (198 [57.7%] vs 106 (63.1%), HR, 0.69, 95% CI, 0.54-0.90, <italic>P</italic>&#x000a0;= 0.005), whereas a higher incidence of VARC-3&#x02013;defined major bleeding (34 [9.9%] vs 6 [3.6%], HR, 2.80, 95% CI, 1.08-7.23; <italic>P</italic>&#x000a0;= 0.03) was noted in women. No differences were observed in the incidences of other outcomes for women vs men, including cardiovascular death, ischemic stroke, hemorrhagic stroke, heart failure rehospitalization, or SVD (<xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref>). Among patients for whom detailed cause-of-mortality records are available, for cardiovascular death, heart failure was the most common cause, followed by infective endocarditis. For noncardiovascular death, pneumonia, including aspiration pneumonia, was the most common cause, followed by malignancy. SVD consists of stenosis and regurgitation, and the mode of failure, by gender, was listed as follows: 48.7% of women, and 37.1% of men, had the etiology of stenosis, and the rest developed regurgitation. The incidence of SVD in each valve type was as follows: for balloon-expandable valves&#x02014;52 of 298 (17.4%) in women, and 25 of 150 (16.7%) in men; for self-expandable valves&#x02014;3 of 45 (6.7%) in women, and 4 of 18 (22.2%) in men.<table-wrap position="float" id="tbl4"><label>Table&#x000a0;4</label><caption><p>Long-term clinical outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Outcome</th><th>Women (n&#x000a0;= 343)</th><th>Men (n&#x000a0;= 168)</th><th>HR (95% CI)</th><th><italic>P</italic></th></tr></thead><tbody><tr><td><bold>All-cause death</bold></td><td align="char">198 (57.7)</td><td align="char">106 (63.1)</td><td align="char">0.69 (0.54&#x02013;0.90)</td><td align="char">0.005</td></tr><tr><td>&#x000a0;Cardiovascular death</td><td align="char">111 (32.4)</td><td align="char">48 (28.6)</td><td align="char">0.79 (0.55&#x02013;1.14)</td><td align="char">0.21</td></tr><tr><td><bold>Structural valve deterioration</bold></td><td align="char">55 (16.0)</td><td align="char">29 (17.3)</td><td align="char">0.97 (0.60&#x02013;1.57)</td><td align="char">0.90</td></tr><tr><td><bold>Stroke</bold></td><td/><td/><td/><td/></tr><tr><td>&#x000a0;Ischemic</td><td align="char">17 (5.0)</td><td align="char">9 (5.4)</td><td align="char">0.77 (0.31&#x02013;1.94)</td><td align="char">0.59</td></tr><tr><td>&#x000a0;Hemorrhagic</td><td align="char">12 (3.5)</td><td align="char">2 (1.2)</td><td align="char">2.59 (0.54&#x02013;12.4)</td><td align="char">0.23</td></tr><tr><td><bold>VARC-3 major bleeding</bold></td><td align="char">34 (9.9)</td><td align="char">6 (3.6)</td><td align="char">2.80 (1.08&#x02013;7.23)</td><td align="char">0.03</td></tr><tr><td><bold>Heart failure readmission</bold></td><td align="char">49 (14.3)</td><td align="char">21 (12.5)</td><td align="char">0.98 (0.57&#x02013;1.69)</td><td align="char">0.94</td></tr></tbody></table><table-wrap-foot><fn><p>Values are count (%), unless otherwise indicated. <italic>P</italic>-values are from the Cox proportional hazards model. The hazard ratio (HR) shown is for women with respect to men. CI, confidence interval; VARC-3, Valve Academic Research Consortium-3.</p></fn></table-wrap-foot></table-wrap><fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Kaplan&#x02013;Meier curves of long-term clinical outcomes: (<bold>A</bold>) all-cause mortality; (<bold>B</bold>) cardiovascular mortality; (<bold>C</bold>) structural valve deterioration.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="p0100">The independent predictors of all-cause mortality and SVD according to gender are presented in <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>. In multivariable analysis, the incidence of all-cause mortality in women was associated independently with a clinical frailty scale score of &#x0003e; 4 (HR, 1.54, 95% CI, 1.14-2.08, <italic>P</italic>&#x000a0;= 0.005). The balloon-expandable valves were associated independently with the development of SVD in women (HR, 3.28, 95% CI, 1.01-10.67, <italic>P</italic>&#x000a0;= 0.049) but not in men. SVD, based on the definition used in this study, was not associated with all-cause mortality in either men or women.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Forest plot of independent predictors for all-cause mortality and structural valve deterioration: (<bold>A</bold>) all-cause mortality; (<bold>B</bold>) structural valve deterioration. CFS, clinical frailty scale; COPD, chronic obstructive pulmonary disease; HALT, hypoattenuated leaflet thickening; LVEF, left ventricular ejection fraction; PPM, prosthesis&#x02013;patient mismatch; PVL, paravalvular leakage; TAVI, transcatheter aortic valve implantation.</p></caption><graphic xlink:href="gr3"/></fig></p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0105">To our knowledge, the present study is the first to evaluate gender differences in long-term outcomes with a median time period of &#x0003e; 5 years. In this study, women were approximately 67.2% of all patients who received the TAVI procedures. The salient findings of the present analysis, comparing women and men, can be summarized as follows:<list list-type="simple" id="olist0010"><list-item id="o0010"><label>&#x02022;</label><p id="p0110">As baseline characteristics, women had smaller anatomic aortic complexes and a higher severity of aortic stenosis than did men.</p></list-item><list-item id="o0015"><label>&#x02022;</label><p id="p0115">Women had more vascular complications than did men.</p></list-item><list-item id="o0020"><label>&#x02022;</label><p id="p0120">Although women have a smaller annulus and a higher severity of aortic stenosis preoperatively, the incidence of PPM and HALT on MDCT did not differ based on gender.</p></list-item><list-item id="o0025"><label>&#x02022;</label><p id="p0125">Women had favourable long-term all-cause mortality, but they were more likely to suffer from major bleeding.</p></list-item><list-item id="o0030"><label>&#x02022;</label><p id="p0130">More than 5 years after TAVI, the incidence of development of SVD was comparable for women vs men.</p></list-item></list></p><p id="p0135">Gender differences in prognosis after TAVI up to the midterm point have been studied, and women showed better prognosis after TAVI than did men.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> However, conclusions regarding long-term prognostic outcomes and the incidence of SVD remain unclear.</p><p id="p0140">In this study, 90% of the women had a small annulus, meaning the area was &#x0003c; 430 mm<sup>2</sup>. Notably, the eligible patients in the current study, the Asian population, tended to have a smaller aortic annulus, compared with the size in previous studies with Westerners, which demonstrated that 82.5% of women had a small annulus.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> In this study, when a conversion was made to the index aortic valve area, no significant differences were observed between genders. Furthermore, in the balloon- and self-expandable valves, the incidence of PPM, which was calculated based on body size, was comparable between the genders. Previous studies also have reported that women are more likely to develop PPM than are men<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref>; however, the smaller body surface area in this study must have favoured avoidance of PPM in the small annulus.</p><p id="p0145">Vascular complications were more common in women than in men in this study, consistent with results of previous reports.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Unavoidable differences are that women have significantly smaller vascular diameters than those in men, and vascular complications are more common in women than in men. However, to prevent that kind of complication as much as possible, careful device selection and attention at the time of final closure are crucial. In the long term, women had more bleeding events than did men. We speculate that one of the reasons for this phenomenon, when taking into account that no gender difference occurred in the rate of anticoagulant medication, may be that lower body weight generally is more common in women, especially elderly Japanese women, and the degree of frailty also is higher in women than it is in men in this study cohort.</p><p id="p0150">The advantage of this study was that MDCT was performed within 30 days after TAVI was analyzed, to detect early subclinical HALT in all patients. However, whether the incidence of HALT is associated with clinical outcomes, in either gender, has not been determined clearly.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> In this study, no gender differences were observed in the incidence of early HALT (15.2% vs 13.2%, <italic>P</italic>&#x000a0;= 0.53). Our previous study found that the early detection of HALT was not associated with medium-term prognosis.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> However, the present study suggests that, in the long term, HALT is not associated with the prognosis or incidence of SVD in women and men. Generally, patients who underwent TAVI were older and were more likely to be at high risk of bleeding, especially women.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Women had more bleeding events in the long term in this study, a result consistent with findings of previous reports (HR, 2.80; 95% CI, 1.08-7.23, <italic>P</italic>&#x000a0;= 0.03). Use of additional anticoagulation to treat HALT, in response to indications, should be considered carefully, taking into account the prognostic impact of both SVD and the bleeding event, especially in this elderly cohort.</p><p id="p0155">Our results showed that all-cause mortality was less common in women than in men (HR, 0.69, 95% CI, 0.54-0.90, <italic>P</italic>&#x000a0;= 0.005). This difference is due to men having more comorbidities before undergoing TAVI, including coronary artery disease, previous percutaneous coronary intervention, and chronic obstructive pulmonary disease. Women have a longer life expectancy than do men, biologically.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> In the current study, women had less comorbidity of coronary artery disease than men did in the patient background, and they had fewer cardiovascular events during long-term follow-up, although this difference was not statistically significant (HR, 0.79, 95% CI, 0.55-1.14, <italic>P</italic>&#x000a0;= 0.21). This result suggests that noncardiovascular deaths are more common in men. Given that previous studies have suggested that pulmonary complications are the main reason for fatal outcomes after a TAVI procedure,<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> the significantly higher prevalence of preoperative chronic obstructive pulmonary disease is considered to contribute to the incidence of noncardiovascular deaths. However, the present study indicated that severe frailty, as indicated by a clinical frailty scale score of &#x0003e; 4, was an independent predictor of a higher incidence of mortality in women. This result suggests that proper frailty assessment before TAVI is performed is important, to improve the long-term prognosis of women.</p><p id="p0160">No difference in the incidence of SVD between women and men was observed during long-term follow-up of echocardiographic data (HR, 0.99, 95% CI 0.78-1.25, <italic>P</italic>&#x000a0;= 0.90). Furthermore, paravalvular leakage that remains less than&#x000a0;mild immediately after TAVI may be a poor prognostic factor for the development of SVD in both genders, but no such finding was statistically significant. In this study, we also showed that balloon-expandable valves were more likely than self-expandable valves to cause SVD in women in the long term. This finding was similar to the results of the <bold>Sm</bold>all <bold>A</bold>nnuli <bold>R</bold>andomized to Evolut or SAPIEN trial (SMART), which showed that self-expandable valves were less likely to cause SVD than were balloon-expandable valves 12 months after TAVI was performed in patients with a small annulus.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Women of an advanced age who had small annuli showed excellent clinical outcomes without developing SVD, even though SVD itself was not associated with mortality; therefore, an appropriate TAVI procedure would improve the long-term prognosis and lifetime management of younger patients.</p><p id="p0165">This study has some limitations. First, as this was an observational cohort study, our findings may have been influenced by unmeasured variables and should be interpreted with caution. However, the potential for bias owing to confounding factors could not be eliminated entirely, despite the use of sophisticated statistical methods. Second, the number of patients included in this study was relatively small, because the study was conducted at a single centre. However, long-term accurate data on valve performance and large number of&#x000a0;MDCT data from within 30 days after TAVI was performed were available in the current study. Third, TAVI procedures performed using former-generation devices were analyzed, because we aimed to investigate the long-term prognosis for or development of SVD. However, the latest valves may have better durability than that of the former ones. Therefore, further studies using newer-generation devices are required. Finally, many patients included in this study were at high risk and were old; thus, only a limited number of patients were able to be followed long term. In the future, the impact of gender differences on the prognosis for or development of SVD should be examined in more patients.</p><sec id="sec3.1"><title>Conclusion</title><p id="p0170">Among those patients with severe aortic stenosis who underwent TAVI, more than 90% of the women had a small annulus. Women may have superior long-term clinical outcomes. The incidence of SVD in women was similar to that in the entire cohort; however, it was higher in a cohort who received a balloon-expandable valve. The association between gender differences and clinical outcomes should be delineated further in future research, using larger numbers of patients.</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Makkar</surname><given-names>R.R.</given-names></name><name><surname>Thourani</surname><given-names>V.H.</given-names></name><name><surname>Mack</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Five-year outcomes of transcatheter or surgical aortic-valve replacement</article-title><source>N&#x000a0;Engl J Med</source><volume>382</volume><year>2020</year><fpage>799</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">31995682</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Thyregod</surname><given-names>H.G.H.</given-names></name><name><surname>Jorgensen</surname><given-names>T.H.</given-names></name><name><surname>Ihlemann</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial</article-title><source>Eur Heart J</source><volume>45</volume><year>2024</year><fpage>1116</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">38321820</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Kapadia</surname><given-names>S.R.</given-names></name><name><surname>Leon</surname><given-names>M.B.</given-names></name><name><surname>Makkar</surname><given-names>R.R.</given-names></name><etal/></person-group><article-title>5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial</article-title><source>Lancet</source><volume>385</volume><year>2015</year><fpage>2485</fpage><lpage>2491</lpage><pub-id pub-id-type="pmid">25788231</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>M.J.</given-names></name><name><surname>Leon</surname><given-names>M.B.</given-names></name><name><surname>Smith</surname><given-names>C.R.</given-names></name><etal/></person-group><article-title>5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial</article-title><source>Lancet</source><volume>385</volume><year>2015</year><fpage>2477</fpage><lpage>2484</lpage><pub-id pub-id-type="pmid">25788234</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>M.J.</given-names></name><name><surname>Leon</surname><given-names>M.B.</given-names></name><name><surname>Thourani</surname><given-names>V.H.</given-names></name><etal/></person-group><article-title>Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients</article-title><source>N&#x000a0;Engl J Med</source><volume>380</volume><year>2019</year><fpage>1695</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">30883058</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Hayashida</surname><given-names>K.</given-names></name><name><surname>Morice</surname><given-names>M.C.</given-names></name><name><surname>Chevalier</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Sex-related differences in clinical presentation and outcome of transcatheter aortic valve implantation for severe aortic stenosis</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>59</volume><year>2012</year><fpage>566</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">22300690</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Sherif</surname><given-names>M.A.</given-names></name><name><surname>Zahn</surname><given-names>R.</given-names></name><name><surname>Gerckens</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Effect of gender differences on 1-year mortality after transcatheter aortic valve implantation for severe aortic stenosis: results from a multicenter real-world registry</article-title><source>Clin Res Cardiol</source><volume>103</volume><year>2014</year><fpage>613</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">24599329</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Van Mieghem</surname><given-names>N.M.</given-names></name><name><surname>Reardon</surname><given-names>M.J.</given-names></name><name><surname>Yakubov</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Clinical outcomes of TAVI or SAVR in men and women with aortic stenosis at intermediate operative risk: a post hoc analysis of the randomised SURTAVI trial</article-title><source>EuroIntervention</source><volume>16</volume><year>2020</year><fpage>833</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">32715995</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Wohrle</surname><given-names>J.</given-names></name><name><surname>Gilard</surname><given-names>M.</given-names></name><name><surname>Didier</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Outcomes after transcatheter aortic valve implantation in men versus women</article-title><source>Am J Cardiol</source><volume>180</volume><year>2022</year><fpage>108</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">35934563</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><collab>Valve Academic Research Consortium (VARC)-3 Writing Committee</collab><name><surname>G&#x000e9;n&#x000e9;reux</surname><given-names>P.</given-names></name><name><surname>Piazza</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research</article-title><source>Eur Heart J</source><volume>42</volume><year>2021</year><fpage>1825</fpage><lpage>1857</lpage><pub-id pub-id-type="pmid">33871579</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Medranda</surname><given-names>G.A.</given-names></name><name><surname>Rogers</surname><given-names>T.</given-names></name><name><surname>Case</surname><given-names>B.C.</given-names></name><etal/></person-group><article-title>Sex disparities in hemodynamics and outcomes in patients who underwent contemporary transcatheter aortic valve implantation</article-title><source>Am J Cardiol</source><volume>174</volume><year>2022</year><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">35550824</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>van Bergeijk</surname><given-names>K.H.</given-names></name><name><surname>van Ginkel</surname><given-names>D.J.</given-names></name><name><surname>Brouwer</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Sex differences in outcomes after transcatheter aortic valve replacement: A POPular TAVI subanalysis</article-title><source>JACC Cardiovasc Interv</source><volume>16</volume><year>2023</year><fpage>1095</fpage><lpage>1102</lpage><pub-id pub-id-type="pmid">37164609</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>R.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name><name><surname>Yashima</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Early and late leaflet thrombosis after transcatheter aortic valve replacement</article-title><source>Circ Cardiovasc Interv</source><volume>12</volume><year>2019</year><object-id pub-id-type="publisher-id">e007349</object-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Salah</surname><given-names>H.M.</given-names></name><name><surname>Almaddah</surname><given-names>N.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Gender differences and outcomes of hypoattenuated leaflet thickening (HALT) following transcatheter aortic valve replacement: a meta-analysis of randomized and cohort studies</article-title><source>Curr Probl Cardiol</source><volume>48</volume><year>2023</year><object-id pub-id-type="publisher-id">101155</object-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="other" id="sref15"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>R.</given-names></name><name><surname>Hayashida</surname><given-names>K.</given-names></name><name><surname>Yamada</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVR [e-pub ahead of print]. JACC Cardiovasc Imaging</article-title><ext-link ext-link-type="doi" xlink:href="10.1016/j.jcmg.2016.11.005" id="intref0010">https://doi.org/10.1016/j.jcmg.2016.11.005</ext-link></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Vina</surname><given-names>J.</given-names></name><name><surname>Sastre</surname><given-names>J.</given-names></name><name><surname>Pallardo</surname><given-names>F.V.</given-names></name><name><surname>Gambini</surname><given-names>J.</given-names></name><name><surname>Borras</surname><given-names>C.</given-names></name></person-group><article-title>Role of mitochondrial oxidative stress to explain the different longevity between genders: protective effect of estrogens</article-title><source>Free Radic Res</source><volume>40</volume><year>2006</year><fpage>1359</fpage><lpage>1365</lpage><pub-id pub-id-type="pmid">17090425</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Wendler</surname><given-names>O.</given-names></name><name><surname>Schymik</surname><given-names>G.</given-names></name><name><surname>Treede</surname><given-names>H.</given-names></name><etal/></person-group><article-title>SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve</article-title><source>Eur Heart J</source><volume>38</volume><year>2017</year><fpage>2717</fpage><lpage>2726</lpage><pub-id pub-id-type="pmid">28605423</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Ravindran</surname><given-names>M.</given-names></name><name><surname>Henning</surname><given-names>K.A.</given-names></name><name><surname>Qiu</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Predictors of long-term cardiovascular versus non-cardiovascular mortality and repeat intervention in patients having transcatheter aortic valve implantation</article-title><source>Am J Cardiol</source><volume>135</volume><year>2020</year><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">32866442</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>H.C.</given-names></name><name><surname>Mehran</surname><given-names>R.</given-names></name><name><surname>Blackman</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Self-expanding or balloon-expandable TAVR in patients with a small aortic annulus</article-title><source>N&#x000a0;Engl J Med</source><volume>390</volume><year>2024</year><fpage>1959</fpage><lpage>1971</lpage><pub-id pub-id-type="pmid">38587261</pub-id>
</element-citation></ref></ref-list><ack id="ack0010"><sec id="sec4"><title>Data Statement</title><p id="p0180">The data in this research are deidentified participant data. The data and materials will not be available to researchers for the purposes of reproducing the results or replicating the procedure.</p></sec><sec id="sec5"><title>Ethics Statement</title><p id="p0185">The Keio University School of Medicine Ethics Committee approved the study protocol (institutional review board reference numbers: 20130270; UMIN000020423).</p></sec><sec id="sec6"><title>Patient Consent</title><p id="p0190">The authors confirm that patient consent forms have been obtained for this article.</p></sec><sec id="sec7"><title>Funding Sources</title><p id="p0195">The authors have no funding sources to declare.</p></sec><sec id="sec8"><title>Disclosures</title><p id="p0175">K.H. is a clinical proctor for Edwards Lifesciences, Abbott Medical, and Medtronic. H.S. and T.T. are clinical proctors at Edwards Lifesciences. H.T. is a clinical screening proctor at Edwards Lifesciences. The other authors have no conflicts of interests to disclose.</p></sec></ack><fn-group><fn id="d36e1101"><p id="ntpara0010">See page 1461 for disclosure information.</p></fn></fn-group></back></article>